Chase Therapeutics is an early-stage specialty pharmaceutical company dedicated to the discovery and development of innovative treatments for neuropsychiatric diseases. The company focuses on translating breakthroughs in neuroscience research into effective therapies aimed at preventing and curing brain dysfunction. Their drug development pipeline includes promising compounds specifically targeting the palliative and neuroprotective treatment of Parkinson’s disease, as well as providing symptomatic relief for major depressive episodes. The lead compounds, CTC-413 and CTC-501, are currently advancing into Phase 2 clinical evaluations, showcasing the company's commitment to developing best-in-class pharmaceuticals.

In addition to their drug candidates, Chase Therapeutics is also developing a bioassay designed to diagnose Parkinson’s disease and related disorders. This bioassay aims to serve as an immediate response outcome measure, particularly useful in clinical trials for neuroprotective treatments. The company’s approach is characterized by a robust patent estate, which protects their innovative compounds and methodologies, reflecting their dedication to advancing therapeutic options for patients suffering from movement and cognitive disorders, as well as major depressive disorder.

United States

Chase Therapeutics is an early-stage, product-based specialty pharmaceutical company focused on the development of better treatments for brain disease.

Chase Therapeutics

Company Details